Current Report · Items 3.01, 5.07 · 8-K
Iris Acquisition Corp
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Submission of Matters to a Vote of Security Holders
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed on Form 8-K on September 10, 2024, and consistent with the Nasdaq Stock Market LLC’s (“Nasdaq”) previous delisting determination, on March 5, 2025, Nasdaq filed a Form 25 with the Securities and Exchange Commission (the “SEC”), notifying the SEC of Nasdaq’s determi…
Company context
Historical securities (12)
ATVCUNASDAQ · UNIT · Historical · closed Jul 26, 2022ATVCWNASDAQ · WARRANT · Historical · closed Jul 27, 2022IRAANASDAQ · EQUITY · Historical · closed Sep 5, 2024IRAAOTC · EQUITY · Historical · closed May 1, 2025IRAAOTC · EQUITY · Historical · closed May 1, 2025IRAAUNASDAQ · UNIT · Historical · closed Sep 4, 2024IRAAUNASDAQ · UNIT · Historical · closed Sep 4, 2024IRAAUNASDAQ · UNIT · Historical · closed Sep 4, 2024IRAAUOTC · UNIT · Historical · closed May 1, 2025IRAAUOTC · UNIT · Historical · closed May 1, 2025IRAAWNASDAQ · WARRANT · Historical · closed Sep 5, 2024IRAAWOTC · WARRANT · Historical · closed May 1, 2025
Disclosure sections
Item 3.01Item 3.01 - Notice of Delisting
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed on Form 8-K on September 10, 2024, and consistent
with the Nasdaq Stock Market LLC’s (“Nasdaq”) previous delisting determination, on March 5, 2025, Nasdaq filed a Form
25 with the Securities and Exchange Commission (the “SEC”), notifying the SEC of Nasdaq’s determination to remove the
Company’s common stock from listing on Nasdaq. The delisting will become effective ten days after the Form 25 was filed.
The Company’s securities have been traded on the OTC Market since
September 6, 2024, and the Company expects that the final delisting action by Nasdaq will have no practical effect on the trading of its
securities on the OTC Market.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders.
On March 4, 2025, Iris Acquisition Corp (“Iris” or the
“Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of
7,000,300 (or 98.95%) of the Company’s issued and outstanding shares of Class A common stock held of record as of January 31, 2025,
the record date for the Special Meeting, were present either in person or by proxy, which constituted a quorum. The Company’s stockholders
voted on the following proposals at the Special Meeting, each of which were approved. The final vote tabulation for each proposal is set
forth below.
Proposal 1 - The Business Combination Proposal. To
adopt the business combination agreement, by and among the Company, Iris Parent Holding Corp. (“ParentCo”), SPAC Merger Sub,
Inc., Liminatus Pharma Merger Sub, Inc. and Liminatus Pharma, LLC and approve the business combination (the “Business Combination”).
For Against Abstained Broker Non-Votes
───────────────────────────────────────────────────────────────
7,000,300 0 0 0
Proposal 2 - The Nasdaq Proposal. To approve,
as required by the rules of the Nasdaq Stock Market, the issuance of ParentCo common stock in the Business Combination (including an accredited
investor’s commitment to purchase 1,500,000 shares of ParentCo common stock at a purchase price per share of $10.00, for an aggregate
purchase price of $15,000,000) in an amount greater than 20% of the number of shares of Iris common stock before such issuance.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Proposal 3 - The Incentive Plan Proposal. To
approve and adopt the ParentCo 2025 Omnibus Equity Incentive Plan.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Proposal 4 - The ParentCo Charter Proposal. To
approve, on an advisory and non-binding basis, ParentCo’s amended and restated certificate of incorporation (the “ParentCo
Certificate of Incorporation”), to be approved and adopted in connection with the Business Combination.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Proposal 5 - Advisory Charter Proposals. To
consider, on an advisory and non-binding basis, the following proposals 5A, 5B, 5C, 5D, 5E and 5F to approve certain governance provisions
in the proposed ParentCo Certificate of Incorporation.
Advisory Charter Proposal 5A - to
amend the name of the public entity to “Liminatus Pharma, Inc.” from “Iris Acquisition Corp”.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Advisory Charter Proposal 5B - to
authorize the issuance of up to 500,000,000 shares of common stock, and up to 1,000,000 shares of “blank check” preferred
stock, the rights, preferences and privileges of which may be designated from time to time by ParentCo’s board of directors.
For Against Abstained
─────────────────────────────────────────
7,000,005 0 0
Advisory Charter Proposal 5C - to
provide that the removal of any director be only for cause and by the affirmative vote of at least 66 2∕3% of ParentCo’s then-outstanding
shares of capital stock entitled to vote generally in the election of directors.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Advisory Charter Proposal 5D - to
make ParentCo’s corporate existence perpetual as opposed to Iris’s corporate existence, which is required to be dissolved
and liquidated 51 months following the closing of its initial public offering if it does not complete a business combination in that time,
and to remove from the proposed ParentCo Certificate of Incorporation the various provisions applicable only to special purpose acquisition
corporations.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Advisory Charter Proposal 5E - to
provide that ParentCo will not be subject to Section 203 of the DGCL.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Advisory Charter Proposal 5F - to
increase the required vote thresholds for approving amendments to the proposed ParentCo Certificate of Incorporation and bylaws to 66
2∕3%.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Proposal 6 - The Election of Directors Proposal. To elect, on an advisory and non-binding basis, the following four directors to serve on the board of directors of the post-combination
company: Nicholas Fernandez, as a Class I director, until the 2026 annual meeting of stockholders, Ji Yeon Baek, as a Class I director,
until the 2026 annual meeting of stockholders, Eun Sook Lee, as a Class II director, until the 2027 annual meeting of stockholders and
Chris Kim, as a Class III director, until the 2028 annual meeting of stockholders, and, in each case, until their respective successors
are duly elected and qualified.
Director For Withhold
───────────────────────────────────────────────────
Nicholas Fernandez 7,000,300 0
Ji Yeon Baek 7,000,300 0
Eun Sook Lee 7,000,300 0
Chris Kim 7,000,300 0
Proposal 7 - The Adjournment Proposal. To approve
the adjournment of the Special Meeting to a later date or dates, if necessary, to permit further solicitation and voting of proxies if,
based upon the tabulated vote at the time of the Special Meeting, there are not sufficient votes to approve the Business Combination Proposal.
For Against Abstained
─────────────────────────────────────────
7,000,300 0 0
Although this proposal would have received sufficient votes to be approved,
no motion to adjourn was made because the adjournment of the Special Meeting was determined not to be necessary or appropriate.
In connection with the Special Meeting, stockholders holding 59,844
public shares properly exercised their right to redeem their shares (and did not withdraw their redemption) for cash at a redemption price
of approximately $11.47 per share, for an aggregate redemption amount of approximately $686,411.